What Is Petrelintide?
Petrelintide is a new weight loss drug. It is still being tested and is not yet available to the public. Two companies are working on it together: Zealand Pharma (a Danish company that invented it) and Roche (a big Swiss drug company).
What makes petrelintide special? It works in a completely different way than the weight loss drugs you have heard about, like Ozempic, Wegovy, or Mounjaro.
How Does It Work? (Simple Explanation)
Imagine your body has a “fullness switch” in your brain. When you eat, your body releases hormones that flip this switch on. That is when you feel satisfied and stop eating.
Most popular weight loss drugs (like Ozempic) copy a hormone called GLP-1. They flip the fullness switch that way.
Petrelintide copies a different hormone called amylin (pronounced “AM-uh-lin”). Amylin is a natural hormone your body makes alongside insulin after you eat. It tells your brain: “You are full. Stop eating.”
Because petrelintide uses a different switch than GLP-1 drugs, it causes far fewer side effects.
The Big Problem It Solves
GLP-1 drugs like Ozempic and Wegovy work well for weight loss. But they have a big problem: many people cannot tolerate the side effects. Nausea, vomiting, and stomach issues are so bad that up to 1 in 3 people stop taking them within a year.
Petrelintide aims to solve this. In the Phase 2 trial (called ZUPREME-1), doctors described its side effects as “placebo-like tolerability.” That means people taking the real drug felt about as good as people taking a sugar pill. That is a big deal.
Who Is It For?
Petrelintide is being developed for people with obesity or who are overweight with health problems (like high blood pressure or type 2 diabetes). It is especially promising for people who tried GLP-1 drugs and had to stop because of side effects.
Where Does It Stand?
| Stage | Status |
| Discovery & Lab Testing | ✅ Complete |
| Phase 1 (Safety in Humans) | ✅ Complete |
| Phase 2 (Does It Work?) | ✅ Complete (ZUPREME-1 trial) |
| Phase 3 (Large-Scale Testing) | 🚀 Starting now (announced April 2026) |
| FDA Approval | ❌ Not yet (likely 2028 or later) |
What Did the Phase 2 Trial Show?
The Phase 2 trial was called ZUPREME-1. Results were presented at the American Diabetes Association (ADA) conference in June 2026. Here is what we learned:
- People lost weight. The weight loss was durable (it kept going over time).
- Side effects were very mild. Researchers called the tolerability “placebo-like” — meaning nearly as gentle as taking nothing at all.
- It was not the most powerful. In terms of total pounds lost, petrelintide did not beat the strongest GLP-1 drugs. But the trade-off is fewer side effects.
Why Does This Matter for Living Longer?
Obesity speeds up aging. It raises the risk of heart disease, diabetes, cancer, dementia, and many other age-related problems. Losing extra weight is one of the most powerful things a person can do to extend their healthy years.
Current weight loss drugs help millions of people — but millions more cannot tolerate them. Petrelintide could open the door for those people to get effective treatment without miserable side effects.
Also, because petrelintide works through a different pathway (amylin, not GLP-1), it could eventually be combined with existing drugs for even better results.
What We Do Not Know Yet
- Long-term safety. We have data from a few hundred people over months, not thousands of people over years.
- Phase 3 results. The big, definitive trials are just starting. Results will not arrive until 2027 or 2028.
- Real-world effectiveness. Clinical trials have strict rules. Real life is messier. We do not know how well it works outside of trials.
- Cost and access. If approved, it will likely be expensive. Insurance coverage is uncertain.
- How it compares head-to-head. There has been no direct trial pitting petrelintide against Ozempic or Mounjaro in the same study.
The Bottom Line
Petrelintide is a new weight loss drug that works through a different mechanism than anything currently available. It may not produce the most dramatic weight loss, but its standout feature is how gentle it is on the body. For the millions of people who cannot tolerate existing weight loss drugs, that could be a game-changer. Phase 3 trials are now starting, and we will know a lot more by 2028.
Sources
- HCP Live. “ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial.” June 7, 2026.
- Fierce Biotech. “ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect.” June 7, 2026.
- Medscape. “Petrelintide Tolerability Could Improve on GLP-1 Challenges.” June 6, 2026.
- BioPharm International. “Zealand Pharma and Roche Advance Petrelintide to Phase 3 for Chronic Weight Management.” April 30, 2026.
- Medical Daily. “A Quiet Breakthrough at ADA 2026: New Therapy Could Fill Gap for Patients Who Can’t Use GLP-1 Drugs.” June 8, 2026.
- Seeking Alpha. “Zealand phase 2 data on petrelintide shows durable weight loss.” June 5, 2026.
Published: July 2026. Last updated: July 2026.